Prostamax is a synthetic tetrapeptide bioregulator derived from prostate tissue research. It's suggested to modulate gene expression. Clinical protocols involve daily intramuscular injections, with doses ranging from 500 mcg to 1 mg, titrated gradually over 8-16 weeks.
- Synthetic tetrapeptide (KEDP) based on prostate tissue research.
- Dosed 500 mcg-1 mg once daily via intramuscular injection.
- Reconstitute a 20 mg vial with 2.0 mL bacteriostatic water for 10 mg/mL.
- Typical cycle is 8-12 weeks, with an optional 16-week extension.
- Proposed to modulate gene expression through epigenetic mechanisms.
Reconstitution
Vial strength
20 mg
Bacteriostatic water
2 mL
Concentration
10 mg/mL
1 unit = 0.01 mL = 100 mcg (0.1 mg)
- 1Draw 2.0 mL of bacteriostatic water using a sterile syringe.
- 2Slowly inject the water down the inside wall of the Prostamax vial, preventing foaming.
- 3Gently swirl or roll the vial until all the peptide powder is dissolved; do not shake.
- 4Label the reconstituted vial with the date and refrigerate it at 2–8 °C (35.6–46.4 °F), protected from light. Use within two weeks.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Protocol detail
| Start | Begin with 500 mcg (0.5 mg) daily. Increment the dose by approximately 250 mcg every two weeks, as tolerated. |
|---|---|
| Target | Aim to reach a daily dose of 1 mg by Weeks 5–8. |
| Frequency | Administer once per day via intramuscular injection. |
| Cycle Length | Typical duration is 8–12 weeks, with an optional extension up to 16 weeks based on individual objectives. |
| Timing | Maintain a consistent daily injection time. Rotate injection sites across various large muscle groups to prevent irritation. |
Overview at a glance
| Goal | To support prostate tissue health and function by leveraging bioregulatory peptide signaling. |
|---|---|
| Schedule | Daily intramuscular injections for 8–12 weeks, with an option to extend to 16 weeks. |
| Dose Range | 500 mcg–1 mg daily, implemented with a gradual titration strategy. |
| Reconstitution | Add 2.0 mL of bacteriostatic water to a 20 mg vial, resulting in a 10 mg/mL concentration for accurate unit measurements. |
| Storage | Lyophilized form can be refrigerated or frozen; once reconstituted, refrigerate and use within two weeks. Avoid freeze-thaw cycles. |
How it works
Prostamax, or KEDP, is a short tetrapeptide thought to influence gene expression through epigenetic mechanisms. It is proposed to interact with chromatin structure and histone proteins. Studies in aged human lymphocytes have shown KEDP can cause pericentromeric chromatin decondensation, potentially reactivating dormant genes. Preclinical rat models of prostatitis indicate that intramuscular administration of KEDP helps reduce inflammatory markers and prevents fibrotic alterations in prostate tissue, suggesting a role in maintaining prostate health.
Reported effects
- Reduced inflammatory markers in prostate tissue (preclinical)
- Prevention of fibrotic changes in prostate (preclinical)
- Favorable effects on prostate weight and histology (preclinical)
- Proposed epigenetic modulation of gene expression
- Generally favorable tolerability profile in preclinical studies
Reported side effects
- Mild injection site reactions (redness, tenderness)
- No published human clinical trials; data from animal models
Storage
Lyophilised (unmixed)
Refrigerate at 4 °C (39.2 °F) short-term or freeze at −20 °C (−4 °F) long-term.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2 weeks.
Supplies
| Peptide vials | For 8 weeks: 2 x 20mg vials; For 12 weeks: 3 x 20mg vials; For 16 weeks: 4 x 20mg vials |
|---|---|
| Insulin syringes (U-100, 30- or 50-unit recommended) | For 8 weeks: 56 syringes; For 12 weeks: 84 syringes; For 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | For 8-16 weeks: 1 x 10 mL bottle (reconstituting with 2.0 mL per vial) |
| Alcohol Swabs | For 8 weeks: ~112 swabs; For 12 weeks: ~168 swabs; For 16 weeks: ~224 swabs |
Important notes
- Use new sterile insulin syringes (30- or 50-unit recommended for precision) or appropriate IM syringes for each injection.
- Dispose of all used syringes and needles properly in a sharps container.
- Rotate injection sites among large muscle groups (deltoid, vastus lateralis, gluteus) to minimize local irritation and discomfort.
- Inject slowly and wait a few seconds before withdrawing the needle to ensure proper dispersion.
- Document your daily dose and track injection site rotation pattern to maintain consistency and monitor progress.
Frequently asked questions
What is the primary route of administration for Prostamax in this protocol?
The primary route in this educational protocol is intramuscular (IM) injection, administered once daily.
How much bacteriostatic water should I use to reconstitute a 20 mg vial of Prostamax?
You should use 2.0 mL of bacteriostatic water for a 20 mg vial. This will give you a concentration of 10 mg/mL.
How long can reconstituted Prostamax be stored, and under what conditions?
Once reconstituted, Prostamax should be refrigerated at 2–8 °C (35.6–46.4 °F) and used within two weeks. It should also be protected from light.
Are there any published human clinical trials for Prostamax?
No, there are no published human clinical trials for Prostamax mentioned. All dosing information is extrapolated from preclinical research and animal models.
Educational reference only. These figures summarise how Prostamax is commonly described in research literature and supplier documentation, including the Prostamax listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Cartalax (20 mg Vial)
Tripeptide bioregulator supporting connective tissue and fibroblast health.
5-Amino-1MQ (10 mg Vial)
Inhibitor of NNMT for metabolic support and fat metabolism.
5-Amino-1MQ (50 mg Vial)
NNMT inhibitor for metabolic support, fat metabolism, and NAD+ levels.
Adamax (10 mg Vial)
Advanced nootropic for enhanced cognition, neuroprotection, and neuroplasticity.